ArticleCureus2025
Prostatic Malakoplakia as a Mimic of Prostate Cancer Progression.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prostatic malakoplakia: a rare case report and literature review.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostatic malakoplakia is a rare chronic inflammatory condition that can present as a cancer mimic and can co-occur with prostate adenocarcinoma. Typically, patients with prostate adenocarcinoma who present with evidence of disease progression while on androgen deprivation therapy (ADT) and a low prostate-specific antigen (PSA) level raise concern for transformation to small cell neuroendocrine carcinoma (SCNEC) of the prostate. A 67-year-old man with known locally advanced prostate adenocarcinoma was admitted with functional decline, radiographic tumor growth, and a low PSA. A repeat prostate biopsy was obtained to assess for transformation to SCNEC, but instead showed concurrent malakoplakia with his stable adenocarcinoma. With antibiotics, his peri-prostatic mass decreased in size, and he experienced an improvement in his functional status, allowing him to resume his ADT. Recurrent urinary tract infections, solid tumors, and immunosuppression are all risk factors for the development of prostatic malakoplakia, which is diagnosed pathologically from biopsy or after prostatectomy. Treatment is either long-term antibiotics or surgical resection. Prostatic malakoplakia should be considered as a mimic of disease progression in patients who have evidence of cancer progression despite a lower-than-expected PSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.